Objective:
To evaluate the effectiveness and injection frequency of aflibercept 8 mg (Eylea HD) in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) based on real-world data.
Key Findings:
- Patients switching to Eylea HD experienced extended injection intervals by approximately 2 to 3 weeks.
- DME patients with poor baseline vision improved by 7.9 to 9.6 letters within 90 days of treatment.
- nAMD patients with poor vision gained 4.4 to 4.5 letters, while those with better vision remained stable.
- Post-loading phase injection intervals averaged 63 to 69 days for treatment-naïve patients.
Interpretation:
Eylea HD may allow for less frequent injections while maintaining or improving visual acuity in patients with nAMD and DME.
Limitations:
- Data derived from electronic health records may have inherent biases.
- Real-world evidence may not fully replicate controlled clinical trial conditions.
Conclusion:
Eylea HD shows promise in reducing injection frequency and improving vision in patients with nAMD and DME, supporting its use in clinical practice.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.